Sanofi India · NSE: SANOFI · BSE: 500674
Q4 FY25 results · Jan–Mar 2025
Sanofi India reported revenue from operations of ₹535.90 crore (down 26.8% from Q4 FY24) and net profit of ₹119.50 crore (down 12.5% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a standalone basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 535.90 | 732.40 | −26.8% | 514.90 | +4.1% |
| Other income | 3.30 | 6.50 | −49.2% | 5.90 | −44.1% |
| Total income | 539.20 | 738.90 | −27.0% | 520.80 | +3.5% |
| Profit before tax | 165.30 | 188.40 | −12.3% | 122.20 | +35.3% |
| Net profit for the period | 119.50 | 136.60 | −12.5% | 91.30 | +30.9% |
| EPS, basic (₹) | 51.89 | 59.31 | −12.5% | 39.64 | +30.9% |
| Net margin (%) | 22.3 | 18.7 | 17.7 |
Standalone
- Filed with BSE
- 14 May 2025, 18:35 IST
- Board meeting
- 14 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE